KR20230116961A - 성장 호르몬 결핍의 검출 및 치료 - Google Patents

성장 호르몬 결핍의 검출 및 치료 Download PDF

Info

Publication number
KR20230116961A
KR20230116961A KR1020237025351A KR20237025351A KR20230116961A KR 20230116961 A KR20230116961 A KR 20230116961A KR 1020237025351 A KR1020237025351 A KR 1020237025351A KR 20237025351 A KR20237025351 A KR 20237025351A KR 20230116961 A KR20230116961 A KR 20230116961A
Authority
KR
South Korea
Prior art keywords
test
growth
children
ghd
testing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237025351A
Other languages
English (en)
Korean (ko)
Inventor
마이클 토너
Original Assignee
암모네트 파마 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암모네트 파마 엘엘씨 filed Critical 암모네트 파마 엘엘씨
Priority to KR1020257020814A priority Critical patent/KR20250102122A/ko
Publication of KR20230116961A publication Critical patent/KR20230116961A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020237025351A 2015-09-21 2016-09-21 성장 호르몬 결핍의 검출 및 치료 Ceased KR20230116961A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257020814A KR20250102122A (ko) 2015-09-21 2016-09-21 성장 호르몬 결핍의 검출 및 치료

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562221191P 2015-09-21 2015-09-21
US62/221,191 2015-09-21
US201662289221P 2016-01-30 2016-01-30
US62/289,221 2016-01-30
PCT/US2016/052800 WO2017053373A1 (en) 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency
KR1020227011483A KR102560838B1 (ko) 2015-09-21 2016-09-21 성장 호르몬 결핍의 검출 및 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011483A Division KR102560838B1 (ko) 2015-09-21 2016-09-21 성장 호르몬 결핍의 검출 및 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257020814A Division KR20250102122A (ko) 2015-09-21 2016-09-21 성장 호르몬 결핍의 검출 및 치료

Publications (1)

Publication Number Publication Date
KR20230116961A true KR20230116961A (ko) 2023-08-04

Family

ID=58276481

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020237025351A Ceased KR20230116961A (ko) 2015-09-21 2016-09-21 성장 호르몬 결핍의 검출 및 치료
KR1020187010804A Active KR102385669B1 (ko) 2015-09-21 2016-09-21 성장 호르몬 결핍의 검출 및 치료
KR1020227011483A Active KR102560838B1 (ko) 2015-09-21 2016-09-21 성장 호르몬 결핍의 검출 및 치료
KR1020257020814A Pending KR20250102122A (ko) 2015-09-21 2016-09-21 성장 호르몬 결핍의 검출 및 치료

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020187010804A Active KR102385669B1 (ko) 2015-09-21 2016-09-21 성장 호르몬 결핍의 검출 및 치료
KR1020227011483A Active KR102560838B1 (ko) 2015-09-21 2016-09-21 성장 호르몬 결핍의 검출 및 치료
KR1020257020814A Pending KR20250102122A (ko) 2015-09-21 2016-09-21 성장 호르몬 결핍의 검출 및 치료

Country Status (23)

Country Link
US (5) US9763919B2 (cg-RX-API-DMAC7.html)
EP (3) EP3352752B1 (cg-RX-API-DMAC7.html)
JP (5) JP6816149B2 (cg-RX-API-DMAC7.html)
KR (4) KR20230116961A (cg-RX-API-DMAC7.html)
CN (2) CN108348501A (cg-RX-API-DMAC7.html)
AU (5) AU2016328969B2 (cg-RX-API-DMAC7.html)
CA (1) CA2998523C (cg-RX-API-DMAC7.html)
CY (1) CY1125183T1 (cg-RX-API-DMAC7.html)
DK (2) DK3939590T3 (cg-RX-API-DMAC7.html)
ES (2) ES2967259T3 (cg-RX-API-DMAC7.html)
FI (1) FI3939590T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220317T1 (cg-RX-API-DMAC7.html)
HU (2) HUE065224T2 (cg-RX-API-DMAC7.html)
IL (1) IL258224B (cg-RX-API-DMAC7.html)
LT (1) LT3352752T (cg-RX-API-DMAC7.html)
PL (2) PL3939590T3 (cg-RX-API-DMAC7.html)
PT (2) PT3939590T (cg-RX-API-DMAC7.html)
RS (1) RS62988B1 (cg-RX-API-DMAC7.html)
SG (2) SG10202010598SA (cg-RX-API-DMAC7.html)
SI (1) SI3352752T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200167T1 (cg-RX-API-DMAC7.html)
UA (1) UA123865C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017053373A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
EP3840854A4 (en) 2018-08-20 2022-06-29 Bessor Pharma, LLC Novel cannabinoids and cannabinoid acids and their derivatives
US11644474B2 (en) * 2020-07-22 2023-05-09 Æterna Zentaris Gmbh Use of macimorelin in assessing growth hormone deficiency in children
GEAP202516774A (en) 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650597A4 (en) * 1992-06-29 1996-12-18 Univ South Florida DIAGNOSTIC METHOD FOR EVALUATING THE AETIOLOGY OF MINOR GROWTH.
US5756507A (en) 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU758160B2 (en) * 1997-08-22 2003-03-20 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
ATE302181T1 (de) * 2000-06-13 2005-09-15 Zentaris Gmbh Verbindungen zur stimulation der sekretion von wachstumshormonen
US20070037861A1 (en) * 2003-09-19 2007-02-15 Pfizer Health Ab Enhanced method of treatment of growth disorders
AU2004288831B2 (en) * 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
US20150119327A1 (en) * 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症

Also Published As

Publication number Publication date
PT3352752T (pt) 2022-03-09
UA123865C2 (uk) 2021-06-16
US20170079961A1 (en) 2017-03-23
SG10202010598SA (en) 2020-11-27
AU2016328969B2 (en) 2020-10-08
ES2967259T3 (es) 2024-04-29
US12539293B2 (en) 2026-02-03
CN108348501A (zh) 2018-07-31
JP2024026112A (ja) 2024-02-28
PL3939590T3 (pl) 2024-03-25
EP3939590B1 (en) 2023-11-29
ES2908423T3 (es) 2022-04-29
PL3352752T3 (pl) 2022-04-19
HUE057831T2 (hu) 2022-06-28
HRP20220317T1 (hr) 2022-05-13
FI3939590T3 (fi) 2023-12-14
KR20250102122A (ko) 2025-07-04
AU2020233715B2 (en) 2021-09-30
CY1125183T1 (el) 2023-06-09
SG10201902424TA (en) 2019-04-29
JP7104768B2 (ja) 2022-07-21
HK1263178A1 (zh) 2020-01-31
AU2024201658C1 (en) 2026-02-12
AU2025237934A1 (en) 2025-10-16
AU2024201658A1 (en) 2024-04-04
JP7389862B2 (ja) 2023-11-30
US20220142989A1 (en) 2022-05-12
US10105352B2 (en) 2018-10-23
US10898472B2 (en) 2021-01-26
DK3939590T3 (da) 2023-12-18
AU2016328969A1 (en) 2018-04-26
KR20180082428A (ko) 2018-07-18
EP3352752A1 (en) 2018-08-01
IL258224A (en) 2018-05-31
JP2018529766A (ja) 2018-10-11
SMT202200167T1 (it) 2022-05-12
IL258224B (en) 2021-10-31
KR102385669B1 (ko) 2022-04-13
CA2998523C (en) 2023-08-01
NZ741142A (en) 2025-05-02
HUE065224T2 (hu) 2024-05-28
RS62988B1 (sr) 2022-03-31
JP2021063096A (ja) 2021-04-22
EP4296679A2 (en) 2023-12-27
US20190015394A1 (en) 2019-01-17
US20180071266A1 (en) 2018-03-15
CA2998523A1 (en) 2017-03-30
JP7724831B2 (ja) 2025-08-18
KR20220047407A (ko) 2022-04-15
AU2020233715A1 (en) 2020-10-22
AU2021254600A1 (en) 2021-11-18
US9763919B2 (en) 2017-09-19
LT3352752T (lt) 2022-04-11
WO2017053373A1 (en) 2017-03-30
CN116459250A (zh) 2023-07-21
EP3939590A1 (en) 2022-01-19
AU2024201658B2 (en) 2025-10-30
JP2022163012A (ja) 2022-10-25
EP3352752B1 (en) 2021-12-22
AU2021254600B2 (en) 2024-02-15
KR102560838B1 (ko) 2023-07-27
SI3352752T1 (sl) 2022-05-31
JP2025170274A (ja) 2025-11-18
PT3939590T (pt) 2024-01-23
JP6816149B2 (ja) 2021-01-20
EP3352752A4 (en) 2019-06-12
US20250213536A1 (en) 2025-07-03
DK3352752T3 (da) 2022-02-28
EP4296679A3 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
US12539293B2 (en) Detecting and treating growth hormone deficiency
US11234969B2 (en) Detecting and treating growth hormone deficiency
HK40096494A (en) Detecting and treating growth hormone deficiency
HK40068057B (en) Detecting and treating growth hormone deficiency
HK40105706A (en) Detecting and treating growth hormone deficiency
HK40068057A (en) Detecting and treating growth hormone deficiency
HK1263178B (en) Detecting and treating growth hormone deficiency

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E601 Decision to refuse application
E801 Decision on dismissal of amendment
P12-X000 Request for amendment of application rejected

St.27 status event code: A-2-2-P10-P12-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104